Cystinuria - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Cystinuria - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cystinuria: Overview
Cystinuria is a rare genetic disorder that causes a buildup of an amino acid called cystine in the urine. This can result in the formation of cystine kidney stones. Cystine stones are often larger, harder and form more frequently than other kinds of kidney stones. Due to the larger stone size, cystine stones may be more difficult to pass, often requiring surgical procedures to remove. Stones can create blockages in the urinary tract and reduce the ability of the kidneys to eliminate waste through urine. The stones also provide sites where bacteria may cause infections. Signs and symptoms of the condition are related to the presence of stones and may include blood in the urine, flank pain, and frequent urinary tract infections.
'Cystinuria - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cystinuria pipeline landscape is provided which includes the disease overview and Cystinuria treatment guidelines. The assessment part of the report embraces, in depth Cystinuria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystinuria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cystinuria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cystinuria Emerging Drugs
Further product details are provided in the report……..
Cystinuria: Therapeutic Assessment
This segment of the report provides insights about the different Cystinuria drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Cystinuria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystinuria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystinuria drugs.
Cystinuria Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Cystinuria - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cystinuria: Overview
Cystinuria is a rare genetic disorder that causes a buildup of an amino acid called cystine in the urine. This can result in the formation of cystine kidney stones. Cystine stones are often larger, harder and form more frequently than other kinds of kidney stones. Due to the larger stone size, cystine stones may be more difficult to pass, often requiring surgical procedures to remove. Stones can create blockages in the urinary tract and reduce the ability of the kidneys to eliminate waste through urine. The stones also provide sites where bacteria may cause infections. Signs and symptoms of the condition are related to the presence of stones and may include blood in the urine, flank pain, and frequent urinary tract infections.
'Cystinuria - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cystinuria pipeline landscape is provided which includes the disease overview and Cystinuria treatment guidelines. The assessment part of the report embraces, in depth Cystinuria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystinuria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cystinuria R&D. The therapies under development are focused on novel approaches to treat/improve Cystinuria.
This segment of the Cystinuria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cystinuria Emerging Drugs
- Bucillamine: Revive Therapeutics
- ADV 7103: Advicenne
Further product details are provided in the report……..
Cystinuria: Therapeutic Assessment
This segment of the report provides insights about the different Cystinuria drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cystinuria
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
- Late-stage products (phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Cystinuria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystinuria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystinuria drugs.
Cystinuria Report Insights
- Cystinuria Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cystinuria drugs?
- How many Cystinuria drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cystinuria?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cystinuria therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cystinuria and their status?
- What are the key designations that have been granted to the emerging drugs?
- Revive Therapeutics
- Advicenne
- Bucillamine
- ADV 7103
Introduction
Executive Summary
Cystinuria: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Cystinuria – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Cystinuria companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cystinuria Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II/III)
• Comparative Analysis
ADV 7103: Advicenne
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Bucillamine: Revive Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Cystinuria Key Companies
Cystinuria Key Products
Cystinuria- Unmet Needs
Cystinuria- Market Drivers and Barriers
Cystinuria- Future Perspectives and Conclusion
Cystinuria Analyst Views
Cystinuria Key Companies
Appendix
Executive Summary
Cystinuria: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Cystinuria – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Cystinuria companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cystinuria Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II/III)
• Comparative Analysis
ADV 7103: Advicenne
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Bucillamine: Revive Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Cystinuria Key Companies
Cystinuria Key Products
Cystinuria- Unmet Needs
Cystinuria- Market Drivers and Barriers
Cystinuria- Future Perspectives and Conclusion
Cystinuria Analyst Views
Cystinuria Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cystinuria
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cystinuria
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cystinuria
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cystinuria
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
